What is CND Life Sciences?
Founded in 2017, CND Life Sciences is a medtech company dedicated to addressing neurodegenerative disorders. The company's focus on this critical area of healthcare positions it within a rapidly evolving and high-impact segment of the life sciences industry. By concentrating on neurological conditions, CND Life Sciences aims to develop innovative solutions that can significantly improve patient outcomes and quality of life.
How much funding has CND Life Sciences raised?
CND Life Sciences has raised a total of $30.3M across 3 funding rounds:
Angel/Seed
$12.5M
Series A
$13.5M
Debt
$4.3M
Angel/Seed (2023): $12.5M, investors not publicly disclosed
Series A (2025): $13.5M led by Tanis Ventures, Cambrian Capital Partners, and BlueStone Ventures
Debt (2026): $4.3M, investors not publicly disclosed
Key Investors in CND Life Sciences
Tanis Ventures
Tanis Ventures is a company in the process of launching new products or services, anticipated to offer significant innovation to their intended clients. Their focus appears to be on creating impactful solutions within their sector.
Cambrian Capital Partners
Cambrian Capital Partners specializes in off-market and innovative investment solutions for private capital, assisting corporations with funding, succession planning, and data-driven growth strategies. They target clients within the condo market and private investment sectors.
BlueStone Ventures
BlueStone Ventures is a construction and development company focused on delivering quality work with personalized service. They manage all stages of construction, from planning to execution, ensuring attention to detail and craftsmanship.
What's next for CND Life Sciences?
The recent strategic investment and overall enterprise-level funding indicate a strong growth trajectory for CND Life Sciences. This capital will likely be deployed to advance its research and development pipeline, potentially expand its clinical trial operations, and bolster its market entry strategies. The company's focus on neurodegenerative disorders suggests a long-term vision for addressing unmet medical needs, positioning it for substantial future impact and potential further financing rounds as it progresses through development milestones.
See full CND Life Sciences company page
